JP2018526447A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018526447A5 JP2018526447A5 JP2018530940A JP2018530940A JP2018526447A5 JP 2018526447 A5 JP2018526447 A5 JP 2018526447A5 JP 2018530940 A JP2018530940 A JP 2018530940A JP 2018530940 A JP2018530940 A JP 2018530940A JP 2018526447 A5 JP2018526447 A5 JP 2018526447A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- molecular weight
- high molecular
- conditioned medium
- weight complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 15
- 150000001720 carbohydrates Chemical class 0.000 claims 9
- 235000014633 carbohydrates Nutrition 0.000 claims 9
- 239000003636 conditioned culture media Substances 0.000 claims 9
- 210000004271 bone marrow stromal cells Anatomy 0.000 claims 7
- 210000001772 Blood Platelets Anatomy 0.000 claims 3
- 229920001287 Chondroitin sulfate Polymers 0.000 claims 3
- KXKPYJOVDUMHGS-OSRGNVMNSA-N Chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 claims 3
- 210000004027 cells Anatomy 0.000 claims 3
- 229940059329 chondroitin sulfate Drugs 0.000 claims 3
- 239000006166 lysate Substances 0.000 claims 3
- 239000002609 media Substances 0.000 claims 3
- 102100015249 VEGFA Human genes 0.000 claims 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 2
- 230000004968 inflammatory condition Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000006228 supernatant Substances 0.000 claims 2
- 102100008428 CCL2 Human genes 0.000 claims 1
- 101700006000 CCL2 Proteins 0.000 claims 1
- 102100016449 CCL5 Human genes 0.000 claims 1
- 102100006400 CSF2 Human genes 0.000 claims 1
- 102100009641 CXCL10 Human genes 0.000 claims 1
- 101710032181 CXCL10 Proteins 0.000 claims 1
- 108010055166 Chemokine CCL5 Proteins 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 101700086956 IFNG Proteins 0.000 claims 1
- 102100016020 IFNG Human genes 0.000 claims 1
- 102000003814 Interleukin-10 Human genes 0.000 claims 1
- 108090000174 Interleukin-10 Proteins 0.000 claims 1
- 102000013462 Interleukin-12 Human genes 0.000 claims 1
- 108010065805 Interleukin-12 Proteins 0.000 claims 1
- 102000003812 Interleukin-15 Human genes 0.000 claims 1
- 108090000172 Interleukin-15 Proteins 0.000 claims 1
- 102000004889 Interleukin-6 Human genes 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 108090001007 Interleukin-8 Proteins 0.000 claims 1
- 102000004890 Interleukin-8 Human genes 0.000 claims 1
- 108010002335 Interleukin-9 Proteins 0.000 claims 1
- 102000000585 Interleukin-9 Human genes 0.000 claims 1
- 101710043203 P23p89 Proteins 0.000 claims 1
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000000240 adjuvant Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 239000001963 growth media Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 230000001225 therapeutic Effects 0.000 claims 1
Claims (15)
- 対象における炎症状態を処置するための、高分子量複合糖質富化馴化培地を含む組成物であって、高分子量複合糖質富化馴化培地がコンドロイチン硫酸を含む、組成物。
- 炎症状態が骨関節炎である、請求項1に記載の組成物。
- 前記処置が、治療有効量の拡大培養されたMSCを投与する工程を更に含む、請求項1又は2に記載の組成物。
- 治療有効量の拡大培養されたMSCをさらに含む、請求項1から3のいずれか一項に記載の組成物。
- 高分子量複合糖質富化馴化培地が、血小板溶解物を含む培地中でMSCを培養することによって調製される、請求項1から4のいずれか一項に記載の組成物。
- ヒト対象の処置のための、拡大培養されたMSCの治療有効量が、細胞約200万から約1000万個の間の用量である、請求項3から5のいずれか一項に記載の組成物。
- ヒト対象の処置のための、拡大培養されたMSCの治療有効量が、細胞約500万個の用量である、請求項3から5のいずれか一項に記載の組成物。
- 高分子量複合糖質富化馴化培地を含む組成物であって、高分子量複合糖質富化馴化培地がコンドロイチン硫酸を含む、組成物。
- 拡大培養されたMSCと高分子量複合糖質富化馴化培地とを含む組成物であって、高分子量複合糖質富化馴化培地がコンドロイチン硫酸を含む、組成物。
- 医薬組成物である、請求項8又は9に記載の組成物。
- 細胞が、前記組成物を含有する容器内に付着していない、請求項10に記載の組成物。
- 高分子量複合糖質富化馴化培地が、血小板溶解物を含む培地中でMSCを培養することによって調製される、請求項8から11のいずれか一項に記載の組成物。
- 請求項8から12のいずれか一項に記載の高分子量複合糖質富化馴化培地と、薬学的に許容される担体、賦形剤又はアジュバントとを含む医薬組成物。
- 安定なセクレトームを含む治療用組成物を調製するための方法であって、前記安定性が、室温で1カ月後に少なくとも60%の活性を保持することを含み、前記方法が、血小板溶解物を含む培地中で、前記培養培地中にセクレトームを分泌させることを可能にするのに十分な時間、MSCを培養する工程と、前記培養から上清を回収する工程とを含み、前記上清を濾過する工程を含まない、方法。
- 安定なセクレトームが、IFN-γ、IL-8、IL-9、IL-12、IL-15、TNF-α、IL-10、MCP-1、RANTES、GM-CSF、IP-10、PDGF-bb、VEGF、IL-6、及びVEGFからなる群から選択される1つ又は複数の因子を含む、請求項14に記載の方法。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021203331A JP2022027928A (ja) | 2015-09-08 | 2021-12-15 | 細胞拡大培養方法及び治療用組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2015903658A AU2015903658A0 (en) | 2015-09-08 | Cell expansion methods and therapeutic compositions | |
| AU2015903658 | 2015-09-08 | ||
| PCT/AU2016/000316 WO2017041133A1 (en) | 2015-09-08 | 2016-09-08 | Cell expansion methods and therapeutic compositions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021203331A Division JP2022027928A (ja) | 2015-09-08 | 2021-12-15 | 細胞拡大培養方法及び治療用組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018526447A JP2018526447A (ja) | 2018-09-13 |
| JP2018526447A5 true JP2018526447A5 (ja) | 2019-10-24 |
| JP6995752B2 JP6995752B2 (ja) | 2022-02-04 |
Family
ID=58240422
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018530940A Active JP6995752B2 (ja) | 2015-09-08 | 2016-09-08 | 細胞拡大培養方法及び治療用組成物 |
| JP2021203331A Pending JP2022027928A (ja) | 2015-09-08 | 2021-12-15 | 細胞拡大培養方法及び治療用組成物 |
| JP2022172508A Pending JP2022186992A (ja) | 2015-09-08 | 2022-10-27 | 細胞拡大培養方法及び治療用組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021203331A Pending JP2022027928A (ja) | 2015-09-08 | 2021-12-15 | 細胞拡大培養方法及び治療用組成物 |
| JP2022172508A Pending JP2022186992A (ja) | 2015-09-08 | 2022-10-27 | 細胞拡大培養方法及び治療用組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20180236003A1 (ja) |
| EP (1) | EP3347449A4 (ja) |
| JP (3) | JP6995752B2 (ja) |
| KR (1) | KR20180043834A (ja) |
| CN (1) | CN108348555B (ja) |
| AU (1) | AU2016321448B2 (ja) |
| CA (1) | CA3035931A1 (ja) |
| HK (1) | HK1252778A1 (ja) |
| TW (1) | TWI760313B (ja) |
| WO (1) | WO2017041133A1 (ja) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3624731A4 (en) * | 2017-05-18 | 2021-02-24 | The Board of Trustees of the Leland Stanford Junior University | TARGETED IN-SITU THERAPEUTIC ADMINISTRATION OF SECRETED FACTORS FROM STEM CELLS FOR THE TREATMENT OF INJURED TISSUES |
| WO2019238952A1 (en) | 2018-06-15 | 2019-12-19 | Marinas Pardo Luis | Pharmaceutical composition for dermatology and uses thereof |
| CN109022360A (zh) * | 2018-07-03 | 2018-12-18 | 湖南未名三胞转化医学科技有限公司 | 自体脂肪干细胞共培养促进外周血造血干细胞增殖方法 |
| CN110106142B (zh) * | 2019-05-30 | 2020-05-12 | 深圳阿尔法生物科技有限公司 | 一种制备“百亿”级脂肪源再生细胞的生产工艺 |
| CN111073857A (zh) * | 2019-12-30 | 2020-04-28 | 深圳爱生再生医学科技有限公司 | 一种治疗关节炎的干细胞生物制品及其制备方法与应用 |
| KR102193175B1 (ko) * | 2020-04-07 | 2020-12-18 | 주식회사 엑소스템텍 | 통증조절인자를 함유한 줄기세포유래 엑소좀 및 그 용도 |
| CO2020012570A1 (es) | 2020-10-08 | 2022-04-08 | Inst Distrital De Ciencia Biotecnologia E Innovacion En Salud Idcbis | Método de estimulación de células mesenquimales para inducir expresión de factores inmunomoduladores |
| KR20230128452A (ko) * | 2020-10-26 | 2023-09-05 | 하다지트 메디칼 리서치 써비시즈 앤드 디벨롭먼트 리미티드 | 중간엽 줄기 세포 및 이의 배양 |
| BR102022016233A2 (pt) * | 2022-08-16 | 2024-02-27 | Omics Biotecnologia Animal Ltda | Concentrado de proteínas e peptídeos derivados de células estromais mesenquimais, método de obtenção e uso de concentrado |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0404656D0 (en) * | 2004-03-02 | 2004-04-07 | Univ Manchester | Treatment of spinal conditions |
| WO2008034803A1 (en) * | 2006-09-18 | 2008-03-27 | Medizinische Universität Graz | Plasma-free platelet lysate for use as a supplement in cell cultures and for the preparation of cell therapeutics |
| HUE066003T2 (hu) * | 2010-08-31 | 2024-06-28 | Gallant Pet Inc | Szisztémás, allogén eredetû õssejtterápiák kutyákban és macskákban betegségek kezelésére |
| EP3546569B1 (en) | 2011-09-23 | 2021-06-16 | Cell Ideas Pty Ltd. | Therapeutics using adipose cells and cell secretions |
| US20140219972A1 (en) * | 2013-02-05 | 2014-08-07 | The Board Of Trustees Of The Leland Stanford Junior University | Tissue engineering using progenitor cells to catalyze tissue formation by primary cells |
| EP3405204A4 (en) * | 2016-08-26 | 2020-03-18 | Restem Llc | COMPOSITION AND METHOD FOR USING CORD STEM CELLS |
-
2016
- 2016-09-08 WO PCT/AU2016/000316 patent/WO2017041133A1/en active Application Filing
- 2016-09-08 TW TW105129180A patent/TWI760313B/zh not_active IP Right Cessation
- 2016-09-08 CN CN201680065321.7A patent/CN108348555B/zh not_active Expired - Fee Related
- 2016-09-08 JP JP2018530940A patent/JP6995752B2/ja active Active
- 2016-09-08 EP EP16843295.3A patent/EP3347449A4/en not_active Withdrawn
- 2016-09-08 KR KR1020187009130A patent/KR20180043834A/ko not_active Application Discontinuation
- 2016-09-08 US US15/758,005 patent/US20180236003A1/en not_active Abandoned
- 2016-09-08 AU AU2016321448A patent/AU2016321448B2/en not_active Ceased
- 2016-09-08 CA CA3035931A patent/CA3035931A1/en active Pending
-
2018
- 2018-09-20 HK HK18112140.4A patent/HK1252778A1/zh unknown
-
2021
- 2021-02-09 US US17/171,885 patent/US20210260129A1/en not_active Abandoned
- 2021-12-15 JP JP2021203331A patent/JP2022027928A/ja active Pending
-
2022
- 2022-10-27 JP JP2022172508A patent/JP2022186992A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018526447A5 (ja) | ||
| SG10201903475TA (en) | New substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs | |
| JP2013177430A5 (ja) | ||
| JP2015529083A5 (ja) | ||
| JP2018009002A5 (ja) | ||
| JP2017519723A5 (ja) | ||
| Wu et al. | c73 new mechanisms and therapies in copd: activating transcription factor 3 represses cigarette smoke-induced il6 and il8 expression via suppressing nuclear factor-κb (nf-κb) activation | |
| CN204908957U (zh) | 一种衣柜裤架 | |
| Özkan et al. | The effects of psychoeducation and telepsychiatric follow-up on social functioning and medication adherence in the patients with schizophrenia | |
| CN103520362B (zh) | 心脑胶囊在制备学习记忆障碍改善药物中的应用 | |
| YU | Latest research topics on allergic asthma | |
| Chen | Efficacy of oral montelukast combined with budesonide suspension inhalation in the treatment of children with cough variant asthma and its effect on inflammatory cytokines | |
| Wu et al. | Activating Transcription Factor 3 Represses Cigarette Smoke-Induced IL6 And IL8 Expression Via Suppressing Nuclear Factor-κB (NF-κB) Activation | |
| Zhong et al. | To investigate the treatment and mechanism of Allicin on Behcet′ s disease | |
| Zhu | A COHORT STUDY OF TRADITION CHINESE MEDICINE COMPREHENSIVE THERAPY FOR TREATMENT OF ISCHEMIC STROKE PATIENTS IN CONVALESCENCE STAGE: THE CHANGE OF FUGLMEYER MOTOR FUNCTION SCORE AFTER FOLLOW-UP | |
| Schlaich et al. | D101 ALLERGY AND ASTHMA: NOVEL REGULATORY PATHWAYS: P2y14 Receptor Deficiency Attenuates Phenotype Of Allergic Airway Inflammation In Mice | |
| Kroll et al. | Risk Mitigation for Hematopoietic Progenitor Cell Infusion-Related Toxicity in Autologous Stem Cell Transplant Recipients | |
| 박민정 et al. | IL-17-deficient allogeneic bone marrow transplantation prevents the induction of collagen-induced arthritis in DBA/1J mice | |
| RU2013111012A (ru) | Способ лечения цитомегаловирусной инфекции | |
| Dewhurst et al. | C34 INSIGHTS INTO COPD PATHOGENESIS FROM PRE-CLINICAL STUDIES: Characterising Subpopulations Of Alveolar And Interstitial Macrophages In Chronic Obstructive Pulmonary Disease | |
| Zare et al. | Application of Stem Cells Condition Medium in Wound Healing | |
| CN105686486A (zh) | 立式圆盘架 | |
| Wu et al. | Alternatively activated dendritic cells derived from systemic | |
| Zhang et al. | The immune function influence of the CD4+ T helper cell after the treatment of continuous blood purification in a porcine model with multiple organ dysfunction syndrome | |
| Yi et al. | Immune modulation by mouse lymphocytes co-culturedwith cord blood-derived multipotent stem cells in Alzheimer's disease model mice |